Allergan 206207-008 – Sponsored by Allergan Pharmaceuticals

Completed Study

This important study resulted in the June 2009 FDA approval of Ozurdex™, a biodegradable implant which enables the extended release and effect of Dexamethasone, a highly potent corticosteroid. This is used in the treatment of patients with macular edema following a Central or Branch Retinal Vein Occlusion.

Return to Vascular Occlusions

Connect

Ophthalmologist Website Design | Accessibility Policy
ALLERGAN 206207-008 Study | Branch Retinal Vein Occlusion in Washington | Branch Retinal Vein Occlusion near Capitol Hill